PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.69%
Revenue growth 1.25-1.5x 3088.T's 3.24%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
1.43%
Gross profit growth 1.25-1.5x 3088.T's 1.19%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
10.35%
EBIT growth below 50% of 3088.T's 49.07%. Michael Burry would suspect deeper competitive or cost structure issues.
2.77%
Operating income growth under 50% of 3088.T's 25.39%. Michael Burry would be concerned about deeper cost or sales issues.
10.77%
Net income growth under 50% of 3088.T's 92.69%. Michael Burry would suspect the firm is falling well behind a key competitor.
10.76%
EPS growth under 50% of 3088.T's 92.70%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
10.76%
Diluted EPS growth under 50% of 3088.T's 92.70%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-0.00%
Share reduction while 3088.T is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3088.T is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
25.00%
10Y revenue/share CAGR at 50-75% of 3088.T's 34.69%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
-4.42%
Negative 5Y CAGR while 3088.T stands at 26.18%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-31.64%
Negative 3Y CAGR while 3088.T stands at 17.44%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
100.00%
Positive long-term OCF/share growth while 3088.T is negative. John Neff would see a structural advantage in sustained cash generation.
100.00%
Positive OCF/share growth while 3088.T is negative. John Neff might see a comparative advantage in operational cash viability.
No Data
No Data available this quarter, please select a different quarter.
128.06%
Net income/share CAGR at 50-75% of 3088.T's 210.18%. Martin Whitman might question if the firm’s product or cost base lags behind.
16.10%
Below 50% of 3088.T's 242.44%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-24.32%
Negative 3Y CAGR while 3088.T is 76.13%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
93.99%
10Y equity/share CAGR 1.25-1.5x 3088.T's 80.20%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
30.55%
Below 50% of 3088.T's 61.36%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-14.41%
Negative 3Y equity/share growth while 3088.T is at 40.41%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.45%
Firm’s AR is declining while 3088.T shows 23.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-2.50%
Inventory is declining while 3088.T stands at 2.01%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-0.38%
Negative asset growth while 3088.T invests at 4.31%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
3.50%
Similar to 3088.T's 3.66%. Walter Schloss finds parallel capital usage or profit distribution strategies.
-0.73%
We’re deleveraging while 3088.T stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
1.10%
We expand SG&A while 3088.T cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.